Related Experiment Video
Updated: Jun 10, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Effects of treatment strategy on endothelial function.
L Tomasoni1, S Sitia, C Borghi
1IRCCS Galeazzi Orthopedic Institute, Department of Health Technologies, Università di Milano, Milan, Italy.
Autoimmunity Reviews
|August 4, 2010
Summary
Hypertension drugs and cholesterol medications offer benefits beyond blood pressure and lipid reduction. These treatments can improve endothelial function, crucial for preventing atherosclerosis and cardiovascular events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Endothelial dysfunction is a hallmark of arterial hypertension, impairing vasodilation and promoting early atherogenesis.
- This dysfunction is potentially reversible, highlighting the importance of therapeutic interventions targeting endothelial health.
Purpose of the Study:
- To review the ancillary effects of antihypertensive drugs and HMGCoA-reductase inhibitors on endothelial function.
- To explore how these medications beyond their primary actions may impact atherosclerosis and cardiovascular event risk.
Main Methods:
- Review of existing scientific literature on antihypertensive medications and HMGCoA-reductase inhibitors.
- Analysis of studies investigating the pleiotropic effects of these drugs on endothelial function and related pathways.
Main Results:
- Antihypertensive drug classes, including ACE inhibitors, angiotensin receptor blockers, and renin inhibitors, positively influence endothelial function by targeting the renin-angiotensin system.
- Newer beta-blockers and phosphodiesterase inhibitors also show potential in improving endothelial function.
- HMGCoA-reductase inhibitors exhibit significant anti-inflammatory and antihypertensive properties, contributing to endothelial health.
Conclusions:
- Preserving or restoring endothelial function in hypertensive patients is vital for inhibiting atherosclerosis and reducing cardiovascular events.
- The pleiotropic effects of antihypertensive and cholesterol-lowering drugs offer a crucial therapeutic advantage beyond their primary indications.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...